schliessen

Filtern

 

Bibliotheken

Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.

BACKGROUNDDespite a lack of long-term data, imatinib has become standard therapy for patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML) who are not candidates for allogeneic stem cell transplantation. In the current study, the authors estimated the incremental cost-effectiven... Full description

Journal Title: Cancer December 1, 2004, Vol.101(11), pp.2574-2583
Main Author: Reed, Shelby D
Other Authors: Anstrom, Kevin J , Ludmer, Jennifer A , Glendenning, G Alastair , Schulman, Kevin A
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0008-543X
Link: http://search.proquest.com/docview/67094845/?pq-origsite=primo
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: proquest67094845
title: Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
format: Article
creator:
  • Reed, Shelby D
  • Anstrom, Kevin J
  • Ludmer, Jennifer A
  • Glendenning, G Alastair
  • Schulman, Kevin A
subjects:
  • Antineoplastic Agents–Administration & Dosage
  • Antineoplastic Combined Chemotherapy Protocols–Economics
  • Benzamides–Therapeutic Use
  • Cohort Studies–Economics
  • Cost-Benefit Analysis–Therapeutic Use
  • Cytarabine–Administration & Dosage
  • Health Care Costs–Economics
  • Humans–Statistics & Numerical Data
  • Imatinib Mesylate–Administration & Dosage
  • Interferon-Alpha–Economics
  • Leukemia, Myelogenous, Chronic, BCR-Abl Positive–Drug Therapy
  • Piperazines–Economics
  • Pyrimidines–Pathology
  • Quality-Adjusted Life Years–Administration & Dosage
  • Retrospective Studies–Economics
  • Survival Analysis–Therapeutic Use
  • Survival Analysis–Administration & Dosage
  • Survival Analysis–Economics
  • Survival Analysis–Therapeutic Use
  • Abridged
  • Antineoplastic Agents
  • Benzamides
  • Interferon-Alpha
  • Piperazines
  • Pyrimidines
  • Cytarabine
  • Imatinib Mesylate
ispartof: Cancer, December 1, 2004, Vol.101(11), pp.2574-2583
description: BACKGROUNDDespite a lack of long-term data, imatinib has become standard therapy for patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML) who are not candidates for allogeneic stem cell transplantation. In the current study, the authors estimated the incremental cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine (IFN+LDAC) as first-line therapy for these patients. METHODSData from the International Randomized Interferon versus STI571 Study and the literature were used to estimate lifetime costs, survival, and quality-adjusted survival. Survival estimates were based on published survival curves for patients who achieved and those who did not achieve a complete cytogenetic response after treatment with interferon-alpha. RESULTSThe mean estimated survival with first-line imatinib therapy was 15.30 years, compared with 9.07 years with IFN+LDAC. Undiscounted lifetime costs were approximately $424,600 with imatinib and $182,800 with IFN+LDAC. Using a 3% discount rate, the incremental survival gain with imatinib was 3.93 life-years and 3.89 quality-adjusted life-years (QALYs). Incremental discounted lifetime costs were found to be $168,100 higher with imatinib, resulting in incremental cost-effectiveness ratios of $43,100 per life-year saved (95% confidence interval [95% CI], $37,600-51,100) and $43,300 per QALY (95% CI, $38,300-49,100). CONCLUSIONSThe results of the current study demonstrate that compared with IFN+LDAC, imatinib is a cost-effective first-line therapy in patients with newly diagnosed chronic-phase CML.
language: eng
source:
identifier: ISSN: 0008-543X
fulltext: fulltext
issn:
  • 0008543X
  • 0008-543X
url: Link


@attributes
ID781753886
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid67094845
sourceidproquest
recordidTN_proquest67094845
sourcesystemOther
pqid67094845
galeid133233583
display
typearticle
titleCost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
creatorReed, Shelby D ; Anstrom, Kevin J ; Ludmer, Jennifer A ; Glendenning, G Alastair ; Schulman, Kevin A
contributorReed, Shelby D (correspondence author) ; Reed, Shelby D (record owner)
ispartofCancer, December 1, 2004, Vol.101(11), pp.2574-2583
identifierISSN: 0008-543X
subject
descriptionBACKGROUNDDespite a lack of long-term data, imatinib has become standard therapy for patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML) who are not candidates for allogeneic stem cell transplantation. In the current study, the authors estimated the incremental cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine (IFN+LDAC) as first-line therapy for these patients. METHODSData from the International Randomized Interferon versus STI571 Study and the literature were used to estimate lifetime costs, survival, and quality-adjusted survival. Survival estimates were based on published survival curves for patients who achieved and those who did not achieve a complete cytogenetic response after treatment with interferon-alpha. RESULTSThe mean estimated survival with first-line imatinib therapy was 15.30 years, compared with 9.07 years with IFN+LDAC. Undiscounted lifetime costs were approximately $424,600 with imatinib and $182,800 with IFN+LDAC. Using a 3% discount rate, the incremental survival gain with imatinib was 3.93 life-years and 3.89 quality-adjusted life-years (QALYs). Incremental discounted lifetime costs were found to be $168,100 higher with imatinib, resulting in incremental cost-effectiveness ratios of $43,100 per life-year saved (95% confidence interval [95% CI], $37,600-51,100) and $43,300 per QALY (95% CI, $38,300-49,100). CONCLUSIONSThe results of the current study demonstrate that compared with IFN+LDAC, imatinib is a cost-effective first-line therapy in patients with newly diagnosed chronic-phase CML.
languageeng
source
version6
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttp://search.proquest.com/docview/67094845/?pq-origsite=primo$$EView_record_in_ProQuest_(subscribers_only)
search
creatorcontrib
0Reed, Shelby D
1Anstrom, Kevin J
2Ludmer, Jennifer A
3Glendenning, G Alastair
4Schulman, Kevin A
titleCost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
descriptionBACKGROUNDDespite a lack of long-term data, imatinib has become standard therapy for patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML) who are not candidates for allogeneic stem cell transplantation. In the current study, the authors estimated the incremental cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine (IFN+LDAC) as first-line therapy for these patients. METHODSData from the International Randomized Interferon versus STI571 Study and the literature were used to estimate lifetime costs, survival, and quality-adjusted survival. Survival estimates were based on published survival curves for patients who achieved and those who did not achieve a complete cytogenetic response after treatment with interferon-alpha. RESULTSThe mean estimated survival with first-line imatinib therapy was 15.30 years, compared with 9.07 years with IFN+LDAC. Undiscounted lifetime costs were approximately $424,600 with imatinib and $182,800 with IFN+LDAC. Using a 3% discount rate, the incremental survival gain with imatinib was 3.93 life-years and 3.89 quality-adjusted life-years (QALYs). Incremental discounted lifetime costs were found to be $168,100 higher with imatinib, resulting in incremental cost-effectiveness ratios of $43,100 per life-year saved (95% confidence interval [95% CI], $37,600-51,100) and $43,300 per QALY (95% CI, $38,300-49,100). CONCLUSIONSThe results of the current study demonstrate that compared with IFN+LDAC, imatinib is a cost-effective first-line therapy in patients with newly diagnosed chronic-phase CML.
subject
0Antineoplastic Agents–Administration & Dosage
1Antineoplastic Combined Chemotherapy Protocols–Economics
2Benzamides–Therapeutic Use
3Cohort Studies–Economics
4Cost-Benefit Analysis–Therapeutic Use
5Cytarabine–Administration & Dosage
6Health Care Costs–Economics
7Humans–Statistics & Numerical Data
8Imatinib Mesylate–Administration & Dosage
9Interferon-Alpha–Economics
10Leukemia, Myelogenous, Chronic, BCR-Abl Positive–Drug Therapy
11Piperazines–Economics
12Pyrimidines–Pathology
13Quality-Adjusted Life Years–Administration & Dosage
14Retrospective Studies–Economics
15Survival Analysis–Therapeutic Use
16Survival Analysis–Administration & Dosage
17Survival Analysis–Economics
18Abridged
19Antineoplastic Agents
20Benzamides
21Interferon-Alpha
22Piperazines
23Pyrimidines
24Cytarabine
25Imatinib Mesylate
general
0English
1MEDLINE (ProQuest)
2ProQuest Biological Science Collection
3ProQuest Natural Science Collection
4ProQuest SciTech Collection
5Biological Science Database
6Natural Science Collection
7SciTech Premium Collection
8Health Research Premium Collection
9Health Research Premium Collection (Alumni edition)
sourceidproquest
recordidproquest67094845
issn
00008543X
10008-543X
rsrctypearticle
creationdate2004
addtitleCancer
searchscope
01007527
11007944
210000004
310000038
410000050
510000120
610000159
710000238
810000253
910000260
1010000270
1110000271
1210000302
13proquest
scope
01007527
11007944
210000004
310000038
410000050
510000120
610000159
710000238
810000253
910000260
1010000270
1110000271
1210000302
13proquest
lsr43
01007527false
11007944false
210000004false
310000038false
410000050false
510000120false
610000159false
710000238false
810000253false
910000260false
1010000270false
1110000271false
1210000302false
contributorReed, Shelby D
startdate20041201
enddate20041201
citationpf 2574 pt 2583 vol 101 issue 11
lsr30VSR-Enriched:[pqid, eissn, doi, galeid]
sort
titleCost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
authorReed, Shelby D ; Anstrom, Kevin J ; Ludmer, Jennifer A ; Glendenning, G Alastair ; Schulman, Kevin A
creationdate20041201
lso0120041201
facets
frbrgroupid6418011143755922828
frbrtype5
newrecords20181218
languageeng
creationdate2004
topic
0Antineoplastic Agents–Administration & Dosage
1Antineoplastic Combined Chemotherapy Protocols–Economics
2Benzamides–Therapeutic Use
3Cohort Studies–Economics
4Cost-Benefit Analysis–Therapeutic Use
5Cytarabine–Administration & Dosage
6Health Care Costs–Economics
7Humans–Statistics & Numerical Data
8Imatinib Mesylate–Administration & Dosage
9Interferon-Alpha–Economics
10Leukemia, Myelogenous, Chronic, BCR-Abl Positive–Drug Therapy
11Piperazines–Economics
12Pyrimidines–Pathology
13Quality-Adjusted Life Years–Administration & Dosage
14Retrospective Studies–Economics
15Survival Analysis–Therapeutic Use
16Survival Analysis–Administration & Dosage
17Survival Analysis–Economics
18Abridged
19Antineoplastic Agents
20Benzamides
21Interferon-Alpha
22Piperazines
23Pyrimidines
24Cytarabine
25Imatinib Mesylate
collection
0MEDLINE (ProQuest)
1ProQuest Biological Science Collection
2ProQuest Natural Science Collection
3ProQuest SciTech Collection
4Biological Science Database
5Natural Science Collection
6SciTech Premium Collection
7Health Research Premium Collection
8Health Research Premium Collection (Alumni edition)
prefilterarticles
rsrctypearticles
creatorcontrib
0Reed, Shelby D
1Anstrom, Kevin J
2Ludmer, Jennifer A
3Glendenning, G Alastair
4Schulman, Kevin A
jtitleCancer
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Reed
1Anstrom
2Ludmer
3Glendenning
4Schulman
aufirst
0Shelby D
1Kevin J
2Jennifer A
3G Alastair
4Kevin A
au
0Reed, Shelby D
1Anstrom, Kevin J
2Ludmer, Jennifer A
3Glendenning, G Alastair
4Schulman, Kevin A
addauReed, Shelby D
atitleCost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
jtitleCancer
risdate20041201
volume101
issue11
spage2574
epage2583
pages2574-2583
issn0008-543X
formatjournal
genrearticle
ristypeJOUR
abstractBACKGROUNDDespite a lack of long-term data, imatinib has become standard therapy for patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML) who are not candidates for allogeneic stem cell transplantation. In the current study, the authors estimated the incremental cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine (IFN+LDAC) as first-line therapy for these patients. METHODSData from the International Randomized Interferon versus STI571 Study and the literature were used to estimate lifetime costs, survival, and quality-adjusted survival. Survival estimates were based on published survival curves for patients who achieved and those who did not achieve a complete cytogenetic response after treatment with interferon-alpha. RESULTSThe mean estimated survival with first-line imatinib therapy was 15.30 years, compared with 9.07 years with IFN+LDAC. Undiscounted lifetime costs were approximately $424,600 with imatinib and $182,800 with IFN+LDAC. Using a 3% discount rate, the incremental survival gain with imatinib was 3.93 life-years and 3.89 quality-adjusted life-years (QALYs). Incremental discounted lifetime costs were found to be $168,100 higher with imatinib, resulting in incremental cost-effectiveness ratios of $43,100 per life-year saved (95% confidence interval [95% CI], $37,600-51,100) and $43,300 per QALY (95% CI, $38,300-49,100). CONCLUSIONSThe results of the current study demonstrate that compared with IFN+LDAC, imatinib is a cost-effective first-line therapy in patients with newly diagnosed chronic-phase CML.
urlhttp://search.proquest.com/docview/67094845/
doi10.1002/cncr.20694
eissn10970142
date2004-12-01